CERRONE GABRIEL 4

Accession 0001104659-13-003842

CIK 0001142380other

Filed

Jan 21, 7:00 PM ET

Accepted

Jan 22, 4:42 PM ET

Size

21.1 KB

Accession

0001104659-13-003842

Form 4

Period: 2013-01-17

DirectorChairman

Transactions

Disposition to Issuer
Stock Options
2013-01-17−75,000→ 0 total
Exercise: $1.50Exp: 2013-06-13→ Common Stock (75,000 underlying)
Disposition to Issuer
Stock Options
2013-01-17−375,000→ 0 total
Exercise: $1.70Exp: 2015-01-10→ Common Stock (375,000 underlying)
Disposition to Issuer
Stock Options
2013-01-17−261,000→ 0 total
Exercise: $1.30From: 2003-04-22Exp: 2013-04-22→ Common Stock (261,000 underlying)
Disposition to Issuer
Stock Options
2013-01-17−100,000→ 0 total
Exercise: $3.20From: 2004-04-26Exp: 2014-04-26→ Common Stock (100,000 underlying)
Disposition to Issuer
Common Stock
2013-01-17−2,184,672→ 0 total(indirect: By Panetta Partners, Ltd.)
Disposition to Issuer
Stock Options
2013-01-17−225,000→ 0 total
Exercise: $0.96Exp: 2017-01-25→ Common Stock (22,500 underlying)
Disposition to Issuer
Stock Options
2013-01-17−390,000→ 0 total
Exercise: $0.26Exp: 2020-01-25→ Common Stock (390,000 underlying)
Disposition to Issuer
Stock Options
2013-01-17−72,055→ 0 total
Exercise: $1.30From: 2003-04-22Exp: 2013-04-22→ Common Stock (72,055 underlying)

Footnotes (6)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of July 20, 2012, as amended October 15, 2012, by and between Synergy Pharmaceuticals Inc ("Synergy") and Callisto Pharmaceuticals, Inc. ("Callisto"), Callisto merged with and into Synergy (the "Merger"). Upon the effective time of the Merger, each share of Callisto common stock was cancelled and exchanged for .1799 shares of Synergy common stock (the "Exchange Ratio"). Each stock option exercisable for shares of Callisto common stock that is outstanding at the effective time of the Merger was assumed by Synergy and converted into a stock option to purchase the number of shares of Synergy's common stock that the holder would have received if such holder had exercised such stock option for shares of Callisto common stock prior to the Merger and exchanged such shares for Synergy common stock in accordance with the Exchange Ratio.
[F2]Mr. Cerrone is the sole director of Panetta Partners Ltd. and in such capacity exercise voting and dispositive control over securities owned by Panetta Partners Ltd. despit him having only a small pecuniary interest in such securities.
[F3]25,000 options vested on each of July 1, 2004, 2005 and 2006, respectively.
[F4]187,500 options vested on each of December 27, 2005 and 2006, respectively.
[F5]75,000 options vested on each of December 31, 2007, 2008 and 2009, respectively.
[F6]130,000 options vested on each of January 25, 2011 and 2012, respectively and 130,000 will vest on January 25, 2013.

Documents

1 file

CALLISTO PHARMACEUTICALS INC

CIK 0001142380

Entity typeother